rethinkPeptides Search
Menu
Study breakdown

Stem Cells Grown in Low Oxygen Produce More Antimicrobial Peptide LL-37, Fighting Infection and Healing Diabetic Wounds in Mice

evidence
The takeaway

Growing amnion-derived stem cells in low-oxygen conditions boosted production of the antimicrobial peptide LL-37, and the resulting conditioned medium killed Staphylococcus aureus and accelerated wound healing in diabetic mice.

Hypoxic culture boosted antimicrobial peptide LL-37 production

Growing stem cells at 1% oxygen instead of 21% increased LL-37 levels enough to kill S. aureus and accelerate wound healing in diabetic mice.

What the researchers found

Amnion-derived mesenchymal stem cells (AMSCs) cultured under hypoxic conditions (1% O2) produced higher levels of the antimicrobial peptide LL-37 compared to normal oxygen conditions (21% O2). The hypoxic conditioned medium significantly inhibited S. aureus growth in vitro.

When delivered as a hydrogel to S. aureus-infected skin wounds in diabetic mice, the hypoxic conditioned medium reduced bacterial counts in the wounds and facilitated wound closure. This dual antimicrobial and wound-healing effect was mediated at least in part by the elevated LL-37 levels.

Why it matters

Diabetic foot ulcers affect millions of people and are a leading cause of non-traumatic limb amputation. Antibiotic resistance makes treating infected wounds increasingly difficult. This study shows that stem cells can be stimulated to produce natural antimicrobial peptides by simply changing their growth conditions — no genetic engineering needed. LL-37 is a human cathelicidin peptide that bacteria have difficulty developing resistance to, making this approach potentially more sustainable than conventional antibiotics.

How the study worked

AMSCs were cultured under normal (21% O2) or hypoxic (1% O2) conditions, and the conditioned medium was collected. LL-37 levels were measured. Antimicrobial activity was tested against S. aureus in vitro. For in vivo testing, skin wounds were created on diabetic mice, infected with S. aureus, and treated with hydrogels containing the conditioned medium. Bacterial counts and wound closure were monitored.

What this study cannot tell us

This is a mouse model study, and diabetic wound healing in mice differs from humans in important ways. The conditioned medium contains many factors besides LL-37, so the contribution of LL-37 specifically was not isolated. The study tested only S. aureus — effectiveness against other wound pathogens is unknown. Long-term outcomes, optimal dosing frequency, and scalability of conditioned medium production were not addressed.

How to read the evidence

This is a preclinical study combining in vitro antimicrobial testing with an in vivo diabetic mouse wound model. The dual validation strengthens the evidence, but it remains at the animal study level with no human data.

When this study was published

Published in 2024, this study is very recent and addresses the pressing clinical challenges of antibiotic resistance and diabetic wound management with a novel approach.

The bigger picture

This study bridges regenerative medicine and antimicrobial peptide research. The finding that hypoxic culture conditions upregulate LL-37 production in mesenchymal stem cells adds a new dimension to stem cell therapy — not just tissue repair, but active infection fighting. As antibiotic resistance grows, antimicrobial peptides like LL-37 are increasingly viewed as next-generation antimicrobials, and this study demonstrates a novel biological production method.

Questions still open

  • Is LL-37 the primary driver of the antimicrobial effect, or do other factors in the hypoxic conditioned medium contribute significantly?
  • Could this approach be combined with standard wound care to improve outcomes for diabetic foot ulcer patients in clinical settings?
  • Would repeated applications of the hydrogel provide additional benefit for chronic, non-healing diabetic wounds?

Common questions

What is LL-37 and why is it better than regular antibiotics?
LL-37 is a natural antimicrobial peptide produced by the human immune system. Unlike conventional antibiotics that target specific bacterial processes, LL-37 kills bacteria by disrupting their cell membranes — a mechanism that makes it much harder for bacteria to develop resistance. This is especially important for treating diabetic wound infections, where antibiotic-resistant bacteria are increasingly common.
Why does low oxygen make stem cells produce more antimicrobial peptides?
Low oxygen (hypoxic) conditions mimic the environment that stem cells experience in the body, particularly at wound sites where oxygen levels are reduced. These conditions activate specific cellular stress responses that upregulate the production of protective molecules including LL-37. By culturing stem cells in 1% oxygen instead of normal 21%, researchers harnessed this natural response to enhance the antimicrobial properties of the stem cell-derived fluid.

Read the original research

Hypoxic culture enhances the antimicrobial activity of amnion-derived mesenchymal stem cells, thereby reducing bacterial load and promoting wound healing in diabetic mice.

Biochemical and biophysical research communications, 739, 150903

Citation

Ishii, Riku; Ohnishi, Shunsuke; Hojo, Masahiro; Ishikawa, Kosuke; Funayama, Emi; Miura, Takahiro; Okubo, Naoto; Okada, Kazufumi; Yamamoto, Yuhei; Maeda, Taku. (2024). Hypoxic culture enhances the antimicrobial activity of amnion-derived mesenchymal stem cells, thereby reducing bacterial load and promoting wound healing in diabetic mice.. Biochemical and biophysical research communications, 739, 150903. https://doi.org/10.1016/j.bbrc.2024.150903